الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 215 |  |  |
| | | from | 215 | | |
Abstract
Phenylpropanolamine HCI (PPA.HCI) regared as an α1- adrenergic agonist , but its main pharmacological action appears to be as an indirectly acting sympathomimetic which causes release of norepinephrine from adrenergic nerve endings. Phenylpropanolamine presumably acts on α-adrenergic receptors in the mucosa of the respiratory tract producing vasoconstriction which results in shrinkage of swollen mucous membrane, reduction of tissue hyperemia , edema and nasal congestion , and an increase in nasal airway patency.it is readily absorbed from GI tract and has a short half-life of 3-6hrs. the problems associated with the frequent administration of this drug could be solved by, for example formulating the drug into controlled -release drug delivery systems (e.g. microspheres or controlled-release tablets).